FDA Approves Molecular Diagnostics Platform for Smaller Labs
By LabMedica International staff writers Posted on 25 Jul 2016 |
Image: The ARIES systems are crafted to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today\'s lean laboratory (Photo courtesy of Luminex).
A latest-generation molecular diagnostics platform due to be released to the clinical laboratory market in the near future has already been cleared for use by the [U.S.] Food and Drug Administration (FDA).
The Luminex Corporation (Austin, TX, USA) has announced the receipt of FDA clearance (510k) for the company's new ARIES M1 System. Having been designed for lower throughput clinical labs, the ARIES M1 System is a fully integrated, sample to answer platform for performing real-time PCR assays.
The ARIES system utilizes the Luminex proprietary MultiCode real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies. MultiCode products, which are used for the early detection of infectious diseases and genetic-based conditions, are centered on the unique MultiCode bases, isoC and isoG. The synthetic isoC:isoG DNA base pair differs from the naturally occurring base pair in its hydrogen bonding pattern. As a result, the MultiCode bases, isoC and isoG, can only base pair with each other. This property enables site-specific incorporation of the isobases during amplification. The isoC and isoG MultiCode bases form the building blocks for Luminex’s next generation MultiCode assays for nucleic acid-based testing.
The ARIES instrument uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and batch testing. An integrated touch screen PC eliminates the need for a separate computer, stand-alone keyboard, and mouse; thus maximizing valuable bench space. The low throughput ARIES M1 System provides one module with the ability to run one to six different assays according to the ARIES Universal Assay Protocol.
"In developing the ARIES family of systems, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory. We are now adding another system based on customer feedback, and in doing so, expanding our market reach," said Homi Shamir, president and CEO of Luminex. "Luminex now has the broadest offering of low-plex and high-plex sample to answer systems for clinical laboratories performing molecular diagnostic testing. And, with the acquisition of NSPH behind us, we can focus on continuing to move products in our pipeline towards commercialization and realizing the value in our newly acquired asset."
The new diagnostics system will be on display at the July 31-August 4, 2016, Annual Scientific Meeting & Clinical Lab Expo of the American Association for Clinical Chemistry in Philadelphia, PA, USA.
Related Links:
Luminex
The Luminex Corporation (Austin, TX, USA) has announced the receipt of FDA clearance (510k) for the company's new ARIES M1 System. Having been designed for lower throughput clinical labs, the ARIES M1 System is a fully integrated, sample to answer platform for performing real-time PCR assays.
The ARIES system utilizes the Luminex proprietary MultiCode real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies. MultiCode products, which are used for the early detection of infectious diseases and genetic-based conditions, are centered on the unique MultiCode bases, isoC and isoG. The synthetic isoC:isoG DNA base pair differs from the naturally occurring base pair in its hydrogen bonding pattern. As a result, the MultiCode bases, isoC and isoG, can only base pair with each other. This property enables site-specific incorporation of the isobases during amplification. The isoC and isoG MultiCode bases form the building blocks for Luminex’s next generation MultiCode assays for nucleic acid-based testing.
The ARIES instrument uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and batch testing. An integrated touch screen PC eliminates the need for a separate computer, stand-alone keyboard, and mouse; thus maximizing valuable bench space. The low throughput ARIES M1 System provides one module with the ability to run one to six different assays according to the ARIES Universal Assay Protocol.
"In developing the ARIES family of systems, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory. We are now adding another system based on customer feedback, and in doing so, expanding our market reach," said Homi Shamir, president and CEO of Luminex. "Luminex now has the broadest offering of low-plex and high-plex sample to answer systems for clinical laboratories performing molecular diagnostic testing. And, with the acquisition of NSPH behind us, we can focus on continuing to move products in our pipeline towards commercialization and realizing the value in our newly acquired asset."
The new diagnostics system will be on display at the July 31-August 4, 2016, Annual Scientific Meeting & Clinical Lab Expo of the American Association for Clinical Chemistry in Philadelphia, PA, USA.
Related Links:
Luminex
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability